Clinical trial
A Combination of Two Currently Approved Drugs to Enhance the Treatment of…
NCT00089869 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00089869 |
|---|---|
| Title | A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | olanzapine, atomoxetine, placebo |
| First posted | Aug 18, 2004 |
| Last update posted | Jul 20, 2006 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: